Inozyme Pharma, Inc. (INZY)
- Previous Close
4.6500 - Open
4.6500 - Bid 4.5300 x 400
- Ask 4.5700 x 100
- Day's Range
4.4600 - 4.6500 - 52 Week Range
2.6890 - 7.7950 - Volume
321,691 - Avg. Volume
691,570 - Market Cap (intraday)
280.824M - Beta (5Y Monthly) 1.54
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3500 - Earnings Date Aug 6, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
20.33
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
www.inozyme.comRecent News: INZY
Performance Overview: INZY
Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INZY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INZY
Valuation Measures
Market Cap
280.82M
Enterprise Value
161.31M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.36
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-32.56%
Return on Equity (ttm)
-69.41%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-77.11M
Diluted EPS (ttm)
-1.3500
Balance Sheet and Cash Flow
Total Cash (mrq)
166.15M
Total Debt/Equity (mrq)
39.24%
Levered Free Cash Flow (ttm)
-52.53M
Research Analysis: INZY
Company Insights: INZY
INZY does not have Company Insights